AustralieFrV1, Main, Exploration, bibRecord, 002321

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

Identifieur interne : 002321 ( Main/Exploration ); précédent : 002320; suivant : 002322

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

Auteurs : Philip A. Thompson [États-Unis] ; Vincent Lévy [France] ; Constantine S. Tam [Australie] ; Chadi Al Nawakil [France] ; François-Xavier Goudot [France] ; Anne Quinquenel [France] ; Loic Ysebaert [France] ; Anne-Sophie Michallet [France] ; Marie-Sarah Dilhuydy [France] ; Eric Van Den Neste [Belgique] ; Jehan Dupuis [France] ; Michael J. Keating [États-Unis] ; Christophe Meune [France] ; Florence Cymbalista [France]

Source :

British journal of haematology [ 1365-2141 ] ; 2016.

RBID : pubmed:27611233

Descripteurs français

KwdFr :
- Adulte d'âge moyen, Antinéoplasiques (effets indésirables), Antinéoplasiques (usage thérapeutique), Femelle, Fibrillation auriculaire (), Fibrillation auriculaire (diagnostic), Fibrillation auriculaire (étiologie), Humains, Hémorragie (), Hémorragie (diagnostic), Hémorragie (étiologie), Inhibiteurs de protéines kinases (effets indésirables), Inhibiteurs de protéines kinases (usage thérapeutique), Leucémie chronique lymphocytaire à cellules B (), Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux), Mâle, Prise en charge de la maladie, Pyrazoles (effets indésirables), Pyrazoles (usage thérapeutique), Pyrimidines (effets indésirables), Pyrimidines (usage thérapeutique), Sujet âgé, Sujet âgé de 80 ans ou plus, Études rétrospectives.
MESH :
- diagnostic : Fibrillation auriculaire, Hémorragie.
- effets indésirables : Antinéoplasiques, Inhibiteurs de protéines kinases, Pyrazoles, Pyrimidines.
- traitement médicamenteux : Leucémie chronique lymphocytaire à cellules B.
- usage thérapeutique : Antinéoplasiques, Inhibiteurs de protéines kinases, Pyrazoles, Pyrimidines.
- étiologie : Fibrillation auriculaire, Hémorragie.
- Adulte d'âge moyen, Femelle, Fibrillation auriculaire, Humains, Hémorragie, Leucémie chronique lymphocytaire à cellules B, Mâle, Prise en charge de la maladie, Sujet âgé, Sujet âgé de 80 ans ou plus, Études rétrospectives.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Antineoplastic Agents (adverse effects), Antineoplastic Agents (therapeutic use), Atrial Fibrillation (diagnosis), Atrial Fibrillation (etiology), Atrial Fibrillation (therapy), Disease Management, Female, Hemorrhage (diagnosis), Hemorrhage (etiology), Hemorrhage (therapy), Humans, Leukemia, Lymphocytic, Chronic, B-Cell (complications), Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy), Male, Middle Aged, Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (therapeutic use), Pyrazoles (adverse effects), Pyrazoles (therapeutic use), Pyrimidines (adverse effects), Pyrimidines (therapeutic use), Retrospective Studies.
MESH :
- chemical , adverse effects : Antineoplastic Agents, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines.
- chemical , therapeutic use : Antineoplastic Agents, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines.
- complications : Leukemia, Lymphocytic, Chronic, B-Cell.
- diagnosis : Atrial Fibrillation, Hemorrhage.
- drug therapy : Leukemia, Lymphocytic, Chronic, B-Cell.
- etiology : Atrial Fibrillation, Hemorrhage.
- therapy : Atrial Fibrillation, Hemorrhage.
- Aged, Aged, 80 and over, Disease Management, Female, Humans, Male, Middle Aged, Retrospective Studies.

Abstract

Atrial fibrillation (AF) occurs in 5-9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non-thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%). Data to guide optimal management are lacking and clinical practice guidelines are urgently needed.

DOI: 10.1111/bjh.14324
PubMed: 27611233

Affiliations:

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.</title>
<author><name sortKey="Thompson, Philip A" sort="Thompson, Philip A" uniqKey="Thompson P" first="Philip A" last="Thompson">Philip A. Thompson</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Levy, Vincent" sort="Levy, Vincent" uniqKey="Levy V" first="Vincent" last="Lévy">Vincent Lévy</name>
<affiliation wicri:level="4"><nlm:affiliation>URC/CRC, GHUPSSD, AP-HP, INSERM U1153, Université Paris 13, Bobigny, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>URC/CRC, GHUPSSD, AP-HP, INSERM U1153, Université Paris 13, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
<author><name sortKey="Tam, Constantine S" sort="Tam, Constantine S" uniqKey="Tam C" first="Constantine S" last="Tam">Constantine S. Tam</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Haematology and Medical Oncology, The Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Haematology and Medical Oncology, The Peter MacCallum Cancer Centre, East Melbourne, Vic.</wicri:regionArea>
<wicri:noRegion>Vic.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Al Nawakil, Chadi" sort="Al Nawakil, Chadi" uniqKey="Al Nawakil C" first="Chadi" last="Al Nawakil">Chadi Al Nawakil</name>
<affiliation wicri:level="4"><nlm:affiliation>URC/CRC, GHUPSSD, AP-HP, INSERM U1153, Université Paris 13, Bobigny, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>URC/CRC, GHUPSSD, AP-HP, INSERM U1153, Université Paris 13, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
<author><name sortKey="Goudot, Francois Xavier" sort="Goudot, Francois Xavier" uniqKey="Goudot F" first="François-Xavier" last="Goudot">François-Xavier Goudot</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Cardiology, GHUPSSD, AP-HP, INSERM UMR s-942, Université Paris 13, Bobigny, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Cardiology, GHUPSSD, AP-HP, INSERM UMR s-942, Université Paris 13, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
<author><name sortKey="Quinquenel, Anne" sort="Quinquenel, Anne" uniqKey="Quinquenel A" first="Anne" last="Quinquenel">Anne Quinquenel</name>
<affiliation wicri:level="3"><nlm:affiliation>Service Hématologie Clinique, Hopital Robert Debré, CHU Reims, Reims, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service Hématologie Clinique, Hopital Robert Debré, CHU Reims, Reims</wicri:regionArea>
<placeName><region type="region">Grand Est</region>
<region type="old region">Champagne-Ardenne</region>
<settlement type="city">Reims</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ysebaert, Loic" sort="Ysebaert, Loic" uniqKey="Ysebaert L" first="Loic" last="Ysebaert">Loic Ysebaert</name>
<affiliation wicri:level="3"><nlm:affiliation>Service d'Hématologie, IUCT-Oncopole, Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'Hématologie, IUCT-Oncopole, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Michallet, Anne Sophie" sort="Michallet, Anne Sophie" uniqKey="Michallet A" first="Anne-Sophie" last="Michallet">Anne-Sophie Michallet</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre Léon Bérard, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Léon Bérard, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dilhuydy, Marie Sarah" sort="Dilhuydy, Marie Sarah" uniqKey="Dilhuydy M" first="Marie-Sarah" last="Dilhuydy">Marie-Sarah Dilhuydy</name>
<affiliation wicri:level="1"><nlm:affiliation>Service d'hématologie, Hopital Haut Leveque, Pessac, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'hématologie, Hopital Haut Leveque, Pessac</wicri:regionArea>
<wicri:noRegion>Pessac</wicri:noRegion>
<wicri:noRegion>Pessac</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Den Neste, Eric" sort="Van Den Neste, Eric" uniqKey="Van Den Neste E" first="Eric" last="Van Den Neste">Eric Van Den Neste</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Cliniques universitaires UCL Saint-Luc, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Haematology, Cliniques universitaires UCL Saint-Luc, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dupuis, Jehan" sort="Dupuis, Jehan" uniqKey="Dupuis J" first="Jehan" last="Dupuis">Jehan Dupuis</name>
<affiliation wicri:level="3"><nlm:affiliation>Lymphoid Malignancies Unit, Henri Mondor University Hospital, Créteil, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Lymphoid Malignancies Unit, Henri Mondor University Hospital, Créteil</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Créteil</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Keating, Michael J" sort="Keating, Michael J" uniqKey="Keating M" first="Michael J" last="Keating">Michael J. Keating</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Meune, Christophe" sort="Meune, Christophe" uniqKey="Meune C" first="Christophe" last="Meune">Christophe Meune</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Cardiology, GHUPSSD, AP-HP, INSERM UMR s-942, Université Paris 13, Bobigny, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Cardiology, GHUPSSD, AP-HP, INSERM UMR s-942, Université Paris 13, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
<author><name sortKey="Cymbalista, Florence" sort="Cymbalista, Florence" uniqKey="Cymbalista F" first="Florence" last="Cymbalista">Florence Cymbalista</name>
<affiliation wicri:level="4"><nlm:affiliation>Service d'Hématologie Biologique, GHUPSSD, AP-HP, U978 INSERM, Université Paris 13, Sorbonne Paris Cité, Labex Inflamex, Bobigny, France. florence.cymbalista@avc.aphp.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'Hématologie Biologique, GHUPSSD, AP-HP, U978 INSERM, Université Paris 13, Sorbonne Paris Cité, Labex Inflamex, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27611233</idno>
<idno type="pmid">27611233</idno>
<idno type="doi">10.1111/bjh.14324</idno>
<idno type="wicri:Area/PubMed/Corpus">001668</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001668</idno>
<idno type="wicri:Area/PubMed/Curation">001646</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001646</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001646</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001646</idno>
<idno type="wicri:Area/Ncbi/Merge">003B19</idno>
<idno type="wicri:Area/Ncbi/Curation">003B19</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">003B19</idno>
<idno type="wicri:Area/Main/Merge">002320</idno>
<idno type="wicri:Area/Main/Curation">002321</idno>
<idno type="wicri:Area/Main/Exploration">002321</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.</title>
<author><name sortKey="Thompson, Philip A" sort="Thompson, Philip A" uniqKey="Thompson P" first="Philip A" last="Thompson">Philip A. Thompson</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Levy, Vincent" sort="Levy, Vincent" uniqKey="Levy V" first="Vincent" last="Lévy">Vincent Lévy</name>
<affiliation wicri:level="4"><nlm:affiliation>URC/CRC, GHUPSSD, AP-HP, INSERM U1153, Université Paris 13, Bobigny, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>URC/CRC, GHUPSSD, AP-HP, INSERM U1153, Université Paris 13, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
<author><name sortKey="Tam, Constantine S" sort="Tam, Constantine S" uniqKey="Tam C" first="Constantine S" last="Tam">Constantine S. Tam</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Haematology and Medical Oncology, The Peter MacCallum Cancer Centre, East Melbourne, Vic., Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Haematology and Medical Oncology, The Peter MacCallum Cancer Centre, East Melbourne, Vic.</wicri:regionArea>
<wicri:noRegion>Vic.</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Al Nawakil, Chadi" sort="Al Nawakil, Chadi" uniqKey="Al Nawakil C" first="Chadi" last="Al Nawakil">Chadi Al Nawakil</name>
<affiliation wicri:level="4"><nlm:affiliation>URC/CRC, GHUPSSD, AP-HP, INSERM U1153, Université Paris 13, Bobigny, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>URC/CRC, GHUPSSD, AP-HP, INSERM U1153, Université Paris 13, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
<author><name sortKey="Goudot, Francois Xavier" sort="Goudot, Francois Xavier" uniqKey="Goudot F" first="François-Xavier" last="Goudot">François-Xavier Goudot</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Cardiology, GHUPSSD, AP-HP, INSERM UMR s-942, Université Paris 13, Bobigny, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Cardiology, GHUPSSD, AP-HP, INSERM UMR s-942, Université Paris 13, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
<author><name sortKey="Quinquenel, Anne" sort="Quinquenel, Anne" uniqKey="Quinquenel A" first="Anne" last="Quinquenel">Anne Quinquenel</name>
<affiliation wicri:level="3"><nlm:affiliation>Service Hématologie Clinique, Hopital Robert Debré, CHU Reims, Reims, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service Hématologie Clinique, Hopital Robert Debré, CHU Reims, Reims</wicri:regionArea>
<placeName><region type="region">Grand Est</region>
<region type="old region">Champagne-Ardenne</region>
<settlement type="city">Reims</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ysebaert, Loic" sort="Ysebaert, Loic" uniqKey="Ysebaert L" first="Loic" last="Ysebaert">Loic Ysebaert</name>
<affiliation wicri:level="3"><nlm:affiliation>Service d'Hématologie, IUCT-Oncopole, Toulouse, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'Hématologie, IUCT-Oncopole, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Michallet, Anne Sophie" sort="Michallet, Anne Sophie" uniqKey="Michallet A" first="Anne-Sophie" last="Michallet">Anne-Sophie Michallet</name>
<affiliation wicri:level="3"><nlm:affiliation>Centre Léon Bérard, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre Léon Bérard, Lyon</wicri:regionArea>
<placeName><region type="region">Auvergne-Rhône-Alpes</region>
<region type="old region">Rhône-Alpes</region>
<settlement type="city">Lyon</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dilhuydy, Marie Sarah" sort="Dilhuydy, Marie Sarah" uniqKey="Dilhuydy M" first="Marie-Sarah" last="Dilhuydy">Marie-Sarah Dilhuydy</name>
<affiliation wicri:level="1"><nlm:affiliation>Service d'hématologie, Hopital Haut Leveque, Pessac, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'hématologie, Hopital Haut Leveque, Pessac</wicri:regionArea>
<wicri:noRegion>Pessac</wicri:noRegion>
<wicri:noRegion>Pessac</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Van Den Neste, Eric" sort="Van Den Neste, Eric" uniqKey="Van Den Neste E" first="Eric" last="Van Den Neste">Eric Van Den Neste</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Haematology, Cliniques universitaires UCL Saint-Luc, Brussels, Belgium.</nlm:affiliation>
<country xml:lang="fr">Belgique</country>
<wicri:regionArea>Department of Haematology, Cliniques universitaires UCL Saint-Luc, Brussels</wicri:regionArea>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dupuis, Jehan" sort="Dupuis, Jehan" uniqKey="Dupuis J" first="Jehan" last="Dupuis">Jehan Dupuis</name>
<affiliation wicri:level="3"><nlm:affiliation>Lymphoid Malignancies Unit, Henri Mondor University Hospital, Créteil, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Lymphoid Malignancies Unit, Henri Mondor University Hospital, Créteil</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Créteil</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Keating, Michael J" sort="Keating, Michael J" uniqKey="Keating M" first="Michael J" last="Keating">Michael J. Keating</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Meune, Christophe" sort="Meune, Christophe" uniqKey="Meune C" first="Christophe" last="Meune">Christophe Meune</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Cardiology, GHUPSSD, AP-HP, INSERM UMR s-942, Université Paris 13, Bobigny, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Cardiology, GHUPSSD, AP-HP, INSERM UMR s-942, Université Paris 13, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
<author><name sortKey="Cymbalista, Florence" sort="Cymbalista, Florence" uniqKey="Cymbalista F" first="Florence" last="Cymbalista">Florence Cymbalista</name>
<affiliation wicri:level="4"><nlm:affiliation>Service d'Hématologie Biologique, GHUPSSD, AP-HP, U978 INSERM, Université Paris 13, Sorbonne Paris Cité, Labex Inflamex, Bobigny, France. florence.cymbalista@avc.aphp.fr.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Service d'Hématologie Biologique, GHUPSSD, AP-HP, U978 INSERM, Université Paris 13, Sorbonne Paris Cité, Labex Inflamex, Bobigny</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Bobigny</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Paris 13</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">British journal of haematology</title>
<idno type="eISSN">1365-2141</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Antineoplastic Agents (adverse effects)</term>
<term>Antineoplastic Agents (therapeutic use)</term>
<term>Atrial Fibrillation (diagnosis)</term>
<term>Atrial Fibrillation (etiology)</term>
<term>Atrial Fibrillation (therapy)</term>
<term>Disease Management</term>
<term>Female</term>
<term>Hemorrhage (diagnosis)</term>
<term>Hemorrhage (etiology)</term>
<term>Hemorrhage (therapy)</term>
<term>Humans</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (complications)</term>
<term>Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Protein Kinase Inhibitors (adverse effects)</term>
<term>Protein Kinase Inhibitors (therapeutic use)</term>
<term>Pyrazoles (adverse effects)</term>
<term>Pyrazoles (therapeutic use)</term>
<term>Pyrimidines (adverse effects)</term>
<term>Pyrimidines (therapeutic use)</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Antinéoplasiques (effets indésirables)</term>
<term>Antinéoplasiques (usage thérapeutique)</term>
<term>Femelle</term>
<term>Fibrillation auriculaire ()</term>
<term>Fibrillation auriculaire (diagnostic)</term>
<term>Fibrillation auriculaire (étiologie)</term>
<term>Humains</term>
<term>Hémorragie ()</term>
<term>Hémorragie (diagnostic)</term>
<term>Hémorragie (étiologie)</term>
<term>Inhibiteurs de protéines kinases (effets indésirables)</term>
<term>Inhibiteurs de protéines kinases (usage thérapeutique)</term>
<term>Leucémie chronique lymphocytaire à cellules B ()</term>
<term>Leucémie chronique lymphocytaire à cellules B (traitement médicamenteux)</term>
<term>Mâle</term>
<term>Prise en charge de la maladie</term>
<term>Pyrazoles (effets indésirables)</term>
<term>Pyrazoles (usage thérapeutique)</term>
<term>Pyrimidines (effets indésirables)</term>
<term>Pyrimidines (usage thérapeutique)</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Études rétrospectives</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Protein Kinase Inhibitors</term>
<term>Pyrazoles</term>
<term>Pyrimidines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Agents</term>
<term>Protein Kinase Inhibitors</term>
<term>Pyrazoles</term>
<term>Pyrimidines</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Atrial Fibrillation</term>
<term>Hemorrhage</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Fibrillation auriculaire</term>
<term>Hémorragie</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Leukemia, Lymphocytic, Chronic, B-Cell</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Inhibiteurs de protéines kinases</term>
<term>Pyrazoles</term>
<term>Pyrimidines</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Atrial Fibrillation</term>
<term>Hemorrhage</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Atrial Fibrillation</term>
<term>Hemorrhage</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Leucémie chronique lymphocytaire à cellules B</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antinéoplasiques</term>
<term>Inhibiteurs de protéines kinases</term>
<term>Pyrazoles</term>
<term>Pyrimidines</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Fibrillation auriculaire</term>
<term>Hémorragie</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Disease Management</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Retrospective Studies</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Femelle</term>
<term>Fibrillation auriculaire</term>
<term>Humains</term>
<term>Hémorragie</term>
<term>Leucémie chronique lymphocytaire à cellules B</term>
<term>Mâle</term>
<term>Prise en charge de la maladie</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Études rétrospectives</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Atrial fibrillation (AF) occurs in 5-9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non-thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%). Data to guide optimal management are lacking and clinical practice guidelines are urgently needed.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Belgique</li>
<li>France</li>
<li>États-Unis</li>
</country>
<region><li>Auvergne-Rhône-Alpes</li>
<li>Champagne-Ardenne</li>
<li>Grand Est</li>
<li>Midi-Pyrénées</li>
<li>Occitanie (région administrative)</li>
<li>Rhône-Alpes</li>
<li>Région de Bruxelles-Capitale</li>
<li>Texas</li>
<li>Île-de-France</li>
</region>
<settlement><li>Bobigny</li>
<li>Bruxelles</li>
<li>Créteil</li>
<li>Lyon</li>
<li>Paris</li>
<li>Reims</li>
<li>Toulouse</li>
</settlement>
<orgName><li>Université Paris 13</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Thompson, Philip A" sort="Thompson, Philip A" uniqKey="Thompson P" first="Philip A" last="Thompson">Philip A. Thompson</name>
</region>
<name sortKey="Keating, Michael J" sort="Keating, Michael J" uniqKey="Keating M" first="Michael J" last="Keating">Michael J. Keating</name>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Levy, Vincent" sort="Levy, Vincent" uniqKey="Levy V" first="Vincent" last="Lévy">Vincent Lévy</name>
</region>
<name sortKey="Al Nawakil, Chadi" sort="Al Nawakil, Chadi" uniqKey="Al Nawakil C" first="Chadi" last="Al Nawakil">Chadi Al Nawakil</name>
<name sortKey="Cymbalista, Florence" sort="Cymbalista, Florence" uniqKey="Cymbalista F" first="Florence" last="Cymbalista">Florence Cymbalista</name>
<name sortKey="Dilhuydy, Marie Sarah" sort="Dilhuydy, Marie Sarah" uniqKey="Dilhuydy M" first="Marie-Sarah" last="Dilhuydy">Marie-Sarah Dilhuydy</name>
<name sortKey="Dupuis, Jehan" sort="Dupuis, Jehan" uniqKey="Dupuis J" first="Jehan" last="Dupuis">Jehan Dupuis</name>
<name sortKey="Goudot, Francois Xavier" sort="Goudot, Francois Xavier" uniqKey="Goudot F" first="François-Xavier" last="Goudot">François-Xavier Goudot</name>
<name sortKey="Meune, Christophe" sort="Meune, Christophe" uniqKey="Meune C" first="Christophe" last="Meune">Christophe Meune</name>
<name sortKey="Michallet, Anne Sophie" sort="Michallet, Anne Sophie" uniqKey="Michallet A" first="Anne-Sophie" last="Michallet">Anne-Sophie Michallet</name>
<name sortKey="Quinquenel, Anne" sort="Quinquenel, Anne" uniqKey="Quinquenel A" first="Anne" last="Quinquenel">Anne Quinquenel</name>
<name sortKey="Ysebaert, Loic" sort="Ysebaert, Loic" uniqKey="Ysebaert L" first="Loic" last="Ysebaert">Loic Ysebaert</name>
</country>
<country name="Australie"><noRegion><name sortKey="Tam, Constantine S" sort="Tam, Constantine S" uniqKey="Tam C" first="Constantine S" last="Tam">Constantine S. Tam</name>
</noRegion>
</country>
<country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Van Den Neste, Eric" sort="Van Den Neste, Eric" uniqKey="Van Den Neste E" first="Eric" last="Van Den Neste">Eric Van Den Neste</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002321 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002321 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:27611233
   |texte=   Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:27611233" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

Serveur d'exploration sur les relations entre la France et l'Australie

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.